Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 In Healthy Volunteers

Next Previous
Trial Profile

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 In Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL 343 (Primary)
  • Indications Amyotrophic lateral sclerosis; Dementia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc

Most Recent Events

  • 27 Apr 2023 Results of pooled analysis from NCT04268784, NCT05006352 assessing stress response presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 02 Dec 2021 Status changed from recruiting to completed.
  • 06 Oct 2021 According to a Denali Therapeutics Inc media release, the company plans to host a webinar for analysts and investors to review the NEALS presentations related to its investigational small molecule therapeutics DNL343 on October 6, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top